---
schema_version: "secwatch.filing_event.v1"
accession: "0001390478-23-000006"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:20:59.010497+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# SELLAS Life Sciences reports FY2022 net loss $41.3M; cash $17.1M, raised $20M in Feb 2023 plus $13M milestone expected

## Summary
- Net loss $41.3M ($2.13 per share) vs $20.7M loss ($1.34 per share) in 2021.
- Cash $17.1M at Dec 31, 2022; subsequent $20M public offering gross proceeds in Feb 2023.
- Phase 3 REGAL AML study interim analysis expected late 2023/early 2024.
- $13M milestone payment from 3D Medicines expected in H1 2023.
- Phase 1 of CDK9 inhibitor GFH009 shows no dose-limiting toxicities; first confirmed CR in AML.

## SEC filing metadata
- accession: 0001390478-23-000006
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000139047823000006/0001390478-23-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000139047823000006/sls-20230316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001390478-23-000006
- JSON: https://secwatch.observer/filing/0001390478-23-000006.json
- Plain text: https://secwatch.observer/filing/0001390478-23-000006.txt

## Key facts
- Earnings Releases
  SELLAS Life Sciences Group, Inc. reported financial results for the year ended December 31, 2022.
  - Period: the year ended December 31, 2022
  - Result: reported results
  source text: On March 16, 2023, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the year ended December 31, 2022 and providing a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1390478/000139047823000006/0001390478-23-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.